查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858007

萬古黴素市場按劑型、給藥途徑、適應症、最終用戶和分銷管道分類－全球預測，2025-2032年

Vancomycin Market by Dosage Form, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，萬古黴素市場規模將成長 11.0576 億美元，複合年成長率為 5.12%。

關鍵市場統計數據
基準年 2024 7.4153億美元
預計年份：2025年 7.7923億美元
預測年份 2032 11.0576億美元
複合年成長率 (%) 5.12%

全面分析影響萬古黴素在醫院、診所和輸液環境中使用的臨床相關性、供應動態和營運壓力。

萬古黴素仍然是醫院環境中的基石抗生素，廣泛用於治療嚴重的革蘭氏陽性感染疾病，以及在抗藥性限制其他藥物使用的情況下進行治療。經過數十年的臨床應用，萬古黴素已從最後的治療方法發展成為經驗性治療和標靶治療方案的重要組成部分，特別適用於治療抗藥性金黃色葡萄球菌感染和某些嚴重的梭狀菌感染。近年來，住院治療路徑的改變、對抗生素管理的重視以及製劑和給藥方式的創新，正在顯著改變臨床醫生和醫療系統應用這種治療方法的方式。

在此臨床背景下，供應鏈動態變化和日益嚴格的監管審查迫使製造商和供應鏈相關人員重新評估其採購、製造地和分銷策略。同時，艱難梭菌感染治療監測、劑量最佳化和口服製劑的進展正在改變處方模式，並對藥房和輸液服務提出了新的營運要求。這些臨床和營運因素與更廣泛的政策和貿易環境相互作用，影響籌資策略、價格談判和醫院的處方決策。

本執行摘要總結了影響價值鏈各相關人員的最顯著趨勢，重點闡述了變革性轉變、關稅主導的壓力、細分市場特有的考量以及區域性動態。該分析旨在為臨床負責人、採購主管、法規事務專業人員和商業團隊提供清晰、可操作的觀點，從而將臨床需求與市場現實相結合。

重要的臨床、生產和政策轉變匯聚在一起，重新定義了整個醫療保健系統中萬古黴素的部署、監測和供應策略。

萬古黴素領域正經歷一系列變革性轉變，這些轉變是由臨床、技術和政策趨勢的融合所驅動，並重新定義了相關人員的優先事項。在臨床方面，人們越來越重視精準給藥和治療藥物監測，以最佳化療效並降低毒性；同時，為了支持個人化治療，方案和實驗室整合的趨勢也在加速發展。

從技術角度來看，針對腸道標靶治療設計的口服製劑的改進正在增強門診艱難梭菌感染疾病的管理，減少某些人群的住院時間，並改變住院患者對腸外產品的需求模式；同時，凍乾工藝和無菌生產的創新正在使注射產品能夠更穩定、更長期地儲存，增強醫院藥房的庫存管理並減少浪費。

在政策層面，更嚴格的抗生素管理指南和對抗生素研發獎勵日益嚴格的審查，正促使支付者和醫療系統更密切地評估臨床路徑和成本效益。供應鏈韌性已成為一項策略重點，製造商正致力於製造外包的多元化，並採用關鍵原料的冗餘採購。這些轉變共同推動相關人員採取整合策略，將卓越的臨床療效、穩健的供應和透明的成本相結合。

美國2025年關稅調整將如何改變必需抗生素和無菌注射劑的採購、庫存和生產決策

美國2025年關稅政策導致某些藥品和醫藥中間體的進口成本上升，對生產、分銷和採購環節造成直接和間接壓力。無菌注射劑和冷凍乾燥藥品中使用的原料和輔料通常來自全球各地，關稅上漲將增加到岸投入成本，迫使生產商和經銷商調整籌資策略和成本分攤方式。

因此，供應鏈相關人員正在評估近岸外包方案，選擇替代供應商，並協商長期合約以穩定單價波動。分銷相關人員正在重新評估其庫存策略，重點關注關鍵無菌產品的安全庫存，以降低出貨時間風險。醫療系統內的採購團隊正在尋求價格保護、靈活的合約條款以及提高成本促進因素的透明度，以支持預算編制週期。

關稅也促使人們討論垂直整合和對本地製造業的投資。一些製造商正在探索在免稅地區擴大產能，或參與公私合作，以確保國內基本抗生素的可靠生產。這些措施將受到監管審查，因為本地生產必須符合無菌和品質標準，這會在策略韌性和即時供應需求之間造成時間上的緊張關係。

臨床醫生可能會感受到採購限制和臨床需求交織的後續影響，例如處方採購慣例、替代方案以及更嚴格的藥品管理標準。積極調整採購方式、實現供應商多元化並完善臨床指南的相關人員，更有可能在應對關稅帶來的成本壓力的同時，維持醫療服務的連續性和療效。

基於可操作的細分洞察，將劑型、給藥途徑、適應症、最終用戶和分銷管道與營運和臨床重點聯繫起來。

細分市場分析揭示了不同劑型、給藥途徑、適應症、最終用戶和分銷管道的臨床和商業考量，這些因素都會影響產品需求和營運重點。按劑型分類，本文檢視了凍乾粉注射、口服製劑和腸外溶液，重點分析了它們在儲存方法、復溶流程和門診適用性方面的差異。冷凍乾燥粉製劑通常需要復溶和嚴格的低溫運輸管理，這決定了藥房和輸液中心的流程；而口服製劑則可用於腸道標靶治療的門診治療。注射液的床邊配製時間較短，但可能有保存期限限制。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 萬古黴素抗藥性腸球菌的出現推動了對下一代糖肽類抗生素的需求。
  • 加強治療藥物監測在重症加護環境中的應用，以最佳化藥物劑量
  • 門診病人中口服萬古黴素用於治療艱難梭菌感染疾病的仿單標示外用藥增加
  • 加速研發長效萬古黴素類似物，以減少給藥頻率並提高病患依從性
  • 萬古黴素：價格壓力不斷增加，促使人們更加關注具有成本效益的學名藥供應鏈策略
  • 擴大對基於奈米顆粒的遞送系統的研究，以增強萬古黴素的靶向抗生素治療
  • 對萬古黴素雜質監管力道的加強促使生產製程創新。
  • 生技公司與學術機構加強合作，以發現新的萬古黴素衍生物

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 萬古黴素市場按劑型分類

  • 注射用凍乾粉
  • 口服
  • 注射液

9. 萬古黴素市場依給藥途徑分類

  • 靜脈注射
  • 口服

10. 萬古黴素市場依適應症分類

  • 艱難梭菌感染疾病
  • 抗藥性金黃色葡萄球菌治療
  • 手術預防

第11章 萬古黴素市場（依最終用戶分類）

  • 門診手術中心
    • 多專科中心
    • 單一專科中心
  • 診所
    • 門診部
    • 專科診所
  • 醫院
    • 社區醫院
    • 三級醫院

12. 萬古黴素市場按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

13. 萬古黴素市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 萬古黴素市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國萬古黴素市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Viatris Inc.
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma Limited
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Ltd.
Product Code: MRR-C002B1C99629

The Vancomycin Market is projected to grow by USD 1,105.76 million at a CAGR of 5.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 741.53 million
Estimated Year [2025] USD 779.23 million
Forecast Year [2032] USD 1,105.76 million
CAGR (%) 5.12%

Comprehensive context on clinical relevance, supply dynamics, and operational pressures shaping vancomycin use across hospitals, clinics, and infusion settings

Vancomycin remains a cornerstone antibiotic in hospital settings, widely deployed to treat serious gram-positive infections and to manage cases where resistance limits the utility of other agents. Over decades of clinical use, vancomycin has evolved from a last-resort therapy to a key element of empiric and targeted treatment protocols, particularly in the management of methicillin-resistant Staphylococcus aureus and certain severe clostridial infections. Recent shifts in inpatient care pathways, an emphasis on antimicrobial stewardship, and innovations in formulation and administration are reshaping how clinicians and health systems deploy this therapy.

Against this clinical backdrop, supply chain dynamics and regulatory scrutiny have intensified, prompting manufacturers and supply-chain stakeholders to re-evaluate sourcing, manufacturing footprints, and distribution strategies. Concurrently, advances in therapeutic monitoring, dose optimization, and oral formulations for Clostridioides difficile management have altered prescribing patterns and created new operational requirements for pharmacies and infusion services. These clinical and operational forces interplay with broader policy and trade environments, influencing procurement strategy, pricing negotiations, and hospital formulary decisions.

This executive summary synthesizes the most salient developments affecting stakeholders across the value chain, highlighting transformative shifts, tariff-driven pressures, segmentation-specific considerations, and regionally distinct dynamics. The analysis is designed to equip clinical leaders, procurement executives, regulatory affairs professionals, and commercial teams with clear, actionable perspectives that bridge clinical imperatives and market realities.

Critical clinical, manufacturing, and policy shifts converging to redefine vancomycin deployment, monitoring, and supply strategies across healthcare systems

The landscape for vancomycin is undergoing a set of transformative shifts driven by converging clinical, technological, and policy trends that are redefining stakeholder priorities. Clinically, there is a stronger emphasis on precision dosing supported by therapeutic drug monitoring to mitigate toxicity while optimizing efficacy, which has accelerated adoption of protocols and laboratory integrations that support individualized therapy.

Technologically, improvements in oral formulations designed for gut-targeted therapy have enhanced outpatient management of Clostridioides difficile infections, reducing hospital lengths of stay for select cohorts and changing demand patterns for inpatient parenteral formulations. Meanwhile, innovations in lyophilization processes and sterile manufacturing are enabling more stable injection products with extended shelf life, which enhances inventory management and reduces wastage for hospital pharmacies.

On the policy front, tighter antimicrobial stewardship guidelines and growing scrutiny of antibiotic pipeline incentives are prompting payers and health systems to more closely evaluate clinical pathways and cost-effectiveness. Supply-chain resilience has become a strategic priority, with manufacturers diversifying contract manufacturing partners and adopting redundant sourcing for critical raw materials. Together, these shifts are pushing stakeholders toward integrated strategies that combine clinical excellence with supply robustness and cost transparency.

How the 2025 tariff shifts in the United States are altering sourcing, inventory, and manufacturing decisions for essential antibiotics and sterile injectables

The 2025 tariff environment in the United States introduced elevated import costs for certain pharmaceuticals and pharmaceutical intermediates, creating direct and indirect pressures across manufacturing, distribution, and procurement functions. Raw materials and excipients used in sterile injectable and lyophilized products are often sourced globally, and increased tariffs can raise landed input costs, necessitating adjustments in sourcing strategies or absorption of costs by manufacturers and distributors.

As a result, supply-chain actors have been evaluating nearshoring options, qualifying alternate suppliers, and negotiating longer-term contracts to stabilize unit-cost volatility. Distribution players have reassessed inventory strategies, placing greater emphasis on safety stock for critical sterile products to mitigate shipment timing risks. Procurement teams within health systems are responding by seeking pricing protections, flexible contract terms, and enhanced transparency into cost drivers to support budgeting cycles.

Tariffs also accelerate conversations about vertical integration and localized manufacturing investments. Some manufacturers are exploring capacity expansions in tariff-exempt jurisdictions or engaging in public-private collaborations to secure reliable domestic production for essential antibiotics. Regulatory oversight accompanies these moves, as local production must meet sterility and quality standards, creating a timeline tension between strategic resilience and immediate supply needs.

Clinicians may feel the downstream effects through formulary reviews, substitution protocols, and tighter stewardship criteria when procurement constraints intersect with clinical demand. Stakeholders who proactively align procurement practices, supplier diversification, and clinical guidelines will be better positioned to navigate tariff-induced cost pressures while maintaining continuity of care and therapeutic effectiveness.

Actionable segmentation-driven insights linking dosage forms, routes, indications, end users, and distribution channels to operational and clinical priorities

Segmentation analysis illuminates distinct clinical and commercial considerations across dosage forms, routes of administration, indications, end users, and distribution channels, each influencing product demand and operational priorities. Based on Dosage Form, market is studied across Lyophilized Powder For Injection, Oral Formulation, and Solution For Injection, which highlights differences in storage, reconstitution workflows, and outpatient applicability. Lyophilized powders often require reconstitution and strict cold-chain management, creating workflow demands in pharmacy and infusion centers, whereas oral formulations enable ambulatory treatment pathways for gut-targeted indications. Solution for injection products reduce bedside preparation time but may impose shorter shelf-life constraints.

Based on Route Of Administration, market is studied across Intravenous and Oral, with intravenous formulations concentrated in acute care settings where rapid systemic exposure is required, and oral routes predominantly used for localized gastrointestinal therapy and outpatient regimens. Therapeutic monitoring and dosing complexity differ substantially by route, influencing laboratory ties and nursing workflows. Based on Indication, market is studied across Clostridioides Difficile Infections, Methicillin Resistant Staphylococcus Aureus Treatment, and Surgical Prophylaxis, which underscores varying clinical protocols, stewardship imperatives, and perioperative stocking practices. C. difficile therapy drives demand for gut-active oral formulations, MRSA treatment centers on systemic parenteral delivery and monitoring, and surgical prophylaxis requires predictable supply within operating suite logistics.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. The Ambulatory Surgical Centers is further studied across Multi Specialty Centers and Single Specialty Centers. The Clinics is further studied across Outpatient Clinics and Specialty Clinics. The Hospitals is further studied across Community Hospitals and Tertiary Care Hospitals, reflecting how institutional scale, procedural mix, and pharmacy capabilities shape product preference and inventory strategies. Finally, based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which identifies divergent procurement practices, dispensing regulations, and patient access considerations. Together, these segmentation lenses create a nuanced picture that supports targeted clinical protocols, procurement decision rules, and commercialization tactics tailored to each stakeholder group.

Regionally differentiated dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive vancomycin availability, procurement, and clinical adoption

Regional dynamics shape availability, regulatory pathways, and clinical utilization patterns for vancomycin in differentiated ways across the globe. In the Americas, healthcare systems exhibit a mix of centralized purchasing in public institutions and competitive private procurement, which influences contracting cycles and supplier negotiations. North American clinical practice has increasingly integrated therapeutic drug monitoring and stewardship protocols that affect inpatient utilization of parenteral formulations, while Latin American markets often face challenges related to supply continuity and procurement transparency, prompting reliance on regional distributors and alternate sourcing strategies.

In Europe, Middle East & Africa, variations in reimbursement policies, procurement mechanisms, and regulatory harmonization create a complex mosaic. Several European markets emphasize national guidelines and tender-based procurement for hospital drugs, which drives supplier consolidation and standardized product specifications. In parts of the Middle East and Africa, infrastructure limitations and logistics hurdles can affect cold-chain reliability for injectable products, leading stakeholders to prioritize stability and shelf-life in supplier selection. Cross-border regulatory alignment efforts and regional manufacturing investments are influencing medium-term supply strategies.

The Asia-Pacific region contains a wide spectrum of markets, from advanced economies with stringent regulatory controls and robust domestic manufacturing to emerging markets where rapid hospital expansion and evolving stewardship frameworks are reshaping demand. Many Asia-Pacific manufacturers play significant roles in global active pharmaceutical ingredient supply, so regional trade policy and manufacturing capacity shifts have outsized implications for global availability. Across all regions, alignment between clinicians, procurement teams, and suppliers-supported by clear data on product handling, monitoring needs, and clinical indications-remains foundational to ensuring reliable patient access.

Strategic company behaviors and supply-chain partnerships that drive resilience, quality differentiation, and long-term institutional relationships in vancomycin supply

The competitive and collaborative dynamics among manufacturers, contract manufacturers, and distributors are central to resilience and innovation in the vancomycin supply chain. Established producers of sterile injectables invest in capacity and quality systems to meet hospital-grade standards, while smaller specialty manufacturers focus on niche formulations or supply to regional markets. Contract manufacturing organizations play a pivotal role in scaling lyophilization capacity and in enabling redundancy when primary sites face disruptions. Distributors and wholesalers that integrate cold-chain logistics and real-time inventory visibility have become strategic partners for health systems aiming to reduce stockouts and manage expiries.

Strategic alliances between manufacturers and hospital systems, such as long-term supply agreements and joint investment in manufacturing resilience, are increasingly common. These collaborations help align production planning with clinical demand and create incentives for process improvements that reduce variability. Pharmaceutical developers are also exploring incremental formulation enhancements that improve handling or extend shelf life, which can improve operational efficiency in pharmacies and infusion centers.

From a regulatory and quality perspective, companies that demonstrate robust compliance, transparent quality data, and rapid responsiveness to adverse events earn preferential consideration in institutional procurement. Firms that proactively engage with clinicians, stewardship committees, and procurement leaders to support training on dosing and monitoring can differentiate themselves beyond price, building long-term relationships grounded in clinical outcomes and operational reliability.

Practical and strategic recommendations for procurement, manufacturing, and clinical leaders to enhance resilience and clinical value in vancomycin supply

Industry leaders should adopt a dual approach that combines immediate operational resilience with medium-term strategic investments to secure clinical continuity and competitive advantage. Near-term actions include diversifying supplier portfolios for critical raw materials and finished products, establishing contractual protections such as price floors and volume commitments, and enhancing inventory management practices with real-time visibility and tiered safety stock aligned to clinical priority levels. Procurement teams should partner closely with antimicrobial stewardship and clinical pharmacy to align stocking policies with evidence-based protocols that reduce unnecessary usage while preserving access for high-priority indications.

Medium-term recommendations emphasize manufacturing resilience and value-based engagement. Investing in regional manufacturing capacity or partnering with contract manufacturers in low-tariff jurisdictions can reduce exposure to trade shocks and logistical delays. Concurrently, companies should invest in formulation improvements that simplify administration and extend shelf life, thereby reducing wastage and operational burdens on hospital pharmacies. Commercial teams should position offerings around total cost of care, emphasizing clinical support services such as dosing guidance, therapeutic drug monitoring facilitation, and education for surgical and ambulatory teams.

Finally, all stakeholders should prioritize data transparency and collaborative contingency planning. Sharing anonymized usage and inventory data across supplier networks and health systems can enable predictive replenishment and targeted interventions during shortages. By combining operational rigor, clinical partnership, and strategic investment, industry leaders can maintain patient access and differentiate through reliability and value.

Methodological overview describing source integration, segmentation logic, and analytical approach used to derive practical vancomycin insights without numeric forecasting

This analysis synthesizes evidence from peer-reviewed clinical literature, regulatory agency guidance, manufacturing quality standards, and documented trade policy developments to create an integrated perspective on vancomycin dynamics. Clinical sections draw on recent guideline updates, antimicrobial stewardship frameworks, and pharmacokinetic-pharmacodynamic literature to describe dosing, monitoring, and indication-specific considerations. Supply-chain and tariff implications are informed by reported changes in trade policy, publicly available customs frameworks, and observable industry responses such as supplier diversification and production adjustments.

The segmentation approach integrates product characteristics, routes of administration, indications, end-user capabilities, and distribution channels to map operational requirements to stakeholder needs. Regionally focused insights are derived from comparative policy analysis, regulatory paradigms, and documented logistics constraints that affect cold-chain and sterile product distribution. Company-level observations incorporate public statements on capacity investments, quality certifications, and strategic partnerships, coupled with industry-standard best practices for sterile manufacturing and distribution.

While the methodology prioritizes triangulation across multiple credible sources and expert practitioner perspectives, the synthesis intentionally avoids speculative numerical projections. Instead, the emphasis is on actionable interpretations of observed trends, validated clinical practices, and operational levers that can be employed by decision-makers to manage risk and capitalize on emerging opportunities.

Concise synthesis emphasizing coordinated clinical, procurement, and manufacturing actions required to preserve access and therapeutic value for vancomycin

In conclusion, vancomycin continues to occupy an essential role in the therapeutic arsenal against serious gram-positive infections, but its near-term trajectory is being reshaped by clinical best practices, formulation innovations, and evolving trade and manufacturing dynamics. Clinicians and health systems face the twin imperatives of optimizing clinical outcomes through precision dosing and stewardship while ensuring continuous supply in the face of tariff-induced cost pressures and global sourcing variability. Hospitals, clinics, and ambulatory surgical centers must therefore synchronize clinical protocols with procurement strategies and supplier engagement to maintain both access and value.

Manufacturers and supply-chain partners that invest in quality, redundancy, and formulation enhancements will be better positioned to meet institutional expectations and to negotiate long-term agreements that balance cost and reliability. Strategic coordination across the value chain-supported by transparent data sharing, aligned contracting, and contingency planning-will be the decisive factor in mitigating disruption and ensuring patient-centered care. By acting on the recommendations outlined in this summary, stakeholders can translate insight into operational resilience and sustained clinical effectiveness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of vancomycin-resistant enterococci driving demand for next-generation glycopeptides
  • 5.2. Increasing integration of therapeutic drug monitoring to optimize vancomycin dosing in critical care settings
  • 5.3. Rising off-label use of oral vancomycin formulations for treatment of Clostridioides difficile infections in outpatient settings
  • 5.4. Accelerated development of long-acting vancomycin analogs for reduced dosing frequency and improved patient compliance
  • 5.5. Growing focus on cost-effective generic vancomycin supply chain strategies amid pricing pressures
  • 5.6. Expanding research into nanoparticle-based vancomycin delivery systems enhancing targeted antimicrobial therapy
  • 5.7. Strengthening regulatory scrutiny on vancomycin impurities prompting manufacturing process innovations
  • 5.8. Increasing collaborations between biotech firms and academic institutions for novel vancomycin derivative discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vancomycin Market, by Dosage Form

  • 8.1. Lyophilized Powder For Injection
  • 8.2. Oral Formulation
  • 8.3. Solution For Injection

9. Vancomycin Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Vancomycin Market, by Indication

  • 10.1. Clostridioides Difficile Infections
  • 10.2. Methicillin Resistant Staphylococcus Aureus Treatment
  • 10.3. Surgical Prophylaxis

11. Vancomycin Market, by End User

  • 11.1. Ambulatory Surgical Centers
    • 11.1.1. Multi Specialty Centers
    • 11.1.2. Single Specialty Centers
  • 11.2. Clinics
    • 11.2.1. Outpatient Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Hospitals
    • 11.3.1. Community Hospitals
    • 11.3.2. Tertiary Care Hospitals

12. Vancomycin Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Vancomycin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vancomycin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vancomycin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
    • 16.3.3. Novartis AG
    • 16.3.4. Viatris Inc.
    • 16.3.5. Fresenius Kabi AG
    • 16.3.6. Hikma Pharmaceuticals PLC
    • 16.3.7. Dr. Reddy's Laboratories Ltd.
    • 16.3.8. Aurobindo Pharma Limited
    • 16.3.9. Sun Pharmaceutical Industries Ltd.
    • 16.3.10. Glenmark Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VANCOMYCIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VANCOMYCIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VANCOMYCIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS VANCOMYCIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS VANCOMYCIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. GCC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. GCC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. GCC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. GCC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. GCC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GCC VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 315. GCC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. GCC VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 320. GCC VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 321. GCC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. GCC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS VANCOMYCIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS VANCOMYCIN MARKET SIZE, BY AMBULATORY SUR